Kadimastem Financials
| KDST Stock | ILA 1,189 14.00 1.19% |
Kadimastem |
Please note, the presentation of Kadimastem's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kadimastem's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kadimastem's management manipulating its earnings.
Kadimastem Stock Summary
Kadimastem competes with Kamada, Teva Pharmaceutical, Tower Semiconductor, Elbit Systems, and Opko Health. Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 28 people.| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0011284614 |
| Business Address | Pinchas Sapir 7, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.kadimastem.com |
| Phone | 972 73 797 1600 |
| Currency | ILA |
You should never invest in Kadimastem without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kadimastem Stock, because this is throwing your money away. Analyzing the key information contained in Kadimastem's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Kadimastem Key Financial Ratios
Kadimastem's financial ratios allow both analysts and investors to convert raw data from Kadimastem's financial statements into concise, actionable information that can be used to evaluate the performance of Kadimastem over time and compare it to other companies across industries.| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Number Of Employees | 23 | |||
| Beta | 0.69 | |||
| Z Score | -3.0 |
Kadimastem Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kadimastem's current stock value. Our valuation model uses many indicators to compare Kadimastem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kadimastem competition to find correlations between indicators driving Kadimastem's intrinsic value. More Info.Kadimastem is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kadimastem by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kadimastem's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Kadimastem Systematic Risk
Kadimastem's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kadimastem volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Kadimastem correlated with the market. If Beta is less than 0 Kadimastem generally moves in the opposite direction as compared to the market. If Kadimastem Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kadimastem is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kadimastem is generally in the same direction as the market. If Beta > 1 Kadimastem moves generally in the same direction as, but more than the movement of the benchmark.
Kadimastem Thematic Clasifications
Kadimastem is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Healthcare | View |
Kadimastem December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kadimastem help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kadimastem. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kadimastem based on widely used predictive technical indicators. In general, we focus on analyzing Kadimastem Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kadimastem's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.32 | |||
| Information Ratio | 0.176 | |||
| Maximum Drawdown | 44.32 | |||
| Value At Risk | (5.82) | |||
| Potential Upside | 12.2 |
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |